Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael E Abram

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|March 9, 2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsFrançois Raffi, Chloe Orkin, Amanda Clarke, et al.
Microbiology Spectrum|August 22, 2022
Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance MonitoringTyler Brady, Tianhui Zhang, Kevin M Tuffy, et al.
The Lancet. Microbe|May 15, 2026
Norovirus GII.4 serological repertoire in older adults after GII.4 ancestral variant vaccination: a post-hoc analysis of a randomised, double-blind, phase 2 trialLisa C Lindesmith, Mark R Zweigart, Paul D Brewer-Jensen, et al.
The Lancet. HIV|April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trialJoel E Gallant, Eric S Daar, François Raffi, et al.
Antimicrobial Agents and Chemotherapy|March 27, 2013
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitnessMichael E Abram, Rebecca M Hluhanich, Derrick D Goodman, et al.
The New England Journal of Medicine|March 2, 2022
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term InfantsLaura L Hammitt, Ron Dagan, Yuan Yuan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 3, 2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyAnton Pozniak, Jose R Arribas, Joseph Gathe, et al.
Nature Communications|July 19, 2023
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trialsBahar Ahani, Kevin M Tuffy, Anastasia A Aksyuk, et al.
BMC Infectious Diseases|June 28, 2020
Global molecular diversity of RSV - the "INFORM RSV" studyAnnefleur C Langedijk, Robert Jan Lebbink, Christiana Naaktgeboren, et al.
Science Translational Medicine|January 25, 2022
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humansYueh-Ming Loo, Patrick M McTamney, Rosalinda H Arends, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Acquired Immune Deficiency Syndromes (1999)|March 9, 2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsFrançois Raffi, Chloe Orkin, Amanda Clarke, et al.
Microbiology Spectrum|August 22, 2022
Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance MonitoringTyler Brady, Tianhui Zhang, Kevin M Tuffy, et al.
The Lancet. Microbe|May 15, 2026
Norovirus GII.4 serological repertoire in older adults after GII.4 ancestral variant vaccination: a post-hoc analysis of a randomised, double-blind, phase 2 trialLisa C Lindesmith, Mark R Zweigart, Paul D Brewer-Jensen, et al.
The Lancet. HIV|April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trialJoel E Gallant, Eric S Daar, François Raffi, et al.
Antimicrobial Agents and Chemotherapy|March 27, 2013
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitnessMichael E Abram, Rebecca M Hluhanich, Derrick D Goodman, et al.
The New England Journal of Medicine|March 2, 2022
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term InfantsLaura L Hammitt, Ron Dagan, Yuan Yuan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 3, 2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyAnton Pozniak, Jose R Arribas, Joseph Gathe, et al.
Nature Communications|July 19, 2023
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trialsBahar Ahani, Kevin M Tuffy, Anastasia A Aksyuk, et al.
BMC Infectious Diseases|June 28, 2020
Global molecular diversity of RSV - the "INFORM RSV" studyAnnefleur C Langedijk, Robert Jan Lebbink, Christiana Naaktgeboren, et al.
Science Translational Medicine|January 25, 2022
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humansYueh-Ming Loo, Patrick M McTamney, Rosalinda H Arends, et al.
Pageof 4